Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Drug: vadastuximab talirine
Drug: Placebo (for 33A)
Drug: Azacitidine

First Posted Date: 2016-03-11

Last Posted Date: 2019-02-12

Lead Sponsor: Seagen Inc.

Target Recruit Count: 19

Registration Number: NCT02706899

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States

and more 31 locations

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma
Grade 3 Follicular Lymphoma
DLBCL
Diffuse Large B-cell Lymphoma

Interventions: Drug: SGN-CD19B

First Posted Date: 2016-03-08

Last Posted Date: 2018-08-13

Lead Sponsor: Seagen Inc.

Target Recruit Count: 44

Registration Number: NCT02702141

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

and more 13 locations

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Phase 2

Completed

Conditions: HER2 Positive Breast Cancer

Interventions: Drug: tucatinib
Drug: capecitabine
Drug: placebo
Drug: trastuzumab

First Posted Date: 2015-11-25

Last Posted Date: 2023-08-14

Lead Sponsor: Seagen Inc.

Target Recruit Count: 612

Registration Number: NCT02614794

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Cancer Treatment Centers of America - Phoenix, Goodyear, Arizona, United States

and more 173 locations

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: vadastuximab talirine

First Posted Date: 2015-11-25

Last Posted Date: 2019-01-09

Lead Sponsor: Seagen Inc.

Target Recruit Count: 14

Registration Number: NCT02614560

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 8 locations

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Phase 2

Terminated

Conditions: Follicular B-cell Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma Refractory

Interventions: Drug: Brentuximab Vedotin
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2015-11-01

Last Posted Date: 2018-10-16

Lead Sponsor: Seagen Inc.

Target Recruit Count: 25

Registration Number: NCT02594163

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Sansum Clinic - West Pueblo, Santa Barbara, California, United States
🇺🇸
Good Samaritan Hospital, Torrance, California, United States

and more 47 locations

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, B-cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular, Grade 3b
Follicular Lymphoma, Grade 3b

Interventions: Drug: denintuzumab mafodotin
Drug: rituximab
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide

First Posted Date: 2015-10-30

Last Posted Date: 2019-05-17

Lead Sponsor: Seagen Inc.

Target Recruit Count: 81

Registration Number: NCT02592876

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Scripps Mercy Cancer Center, San Diego, California, United States

and more 26 locations

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: nivolumab

First Posted Date: 2015-10-08

Last Posted Date: 2022-11-08

Lead Sponsor: Seagen Inc.

Target Recruit Count: 93

Registration Number: NCT02572167

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 10 locations

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Phase 1

Completed

Conditions: Bladder Cancer
Ovary Cancer
Endometrium Cancer
Prostate Cancer (CRPC)
Lung Cancer (NSCLC)
Esophagus Cancer
Cervix Cancer

Interventions: Drug: Tisotumab vedotin (HuMax-TF-ADC)

First Posted Date: 2015-09-16

Last Posted Date: 2021-04-08

Lead Sponsor: Seagen Inc.

Target Recruit Count: 33

Registration Number: NCT02552121

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇧🇪
Institut Jules Bordet, Bruxelles, Brussels, Belgium
🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Flemish Brabant, Belgium

and more 13 locations

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Brentuximab vedotin
Drug: Placebo

First Posted Date: 2015-08-27

Last Posted Date: 2018-06-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 20

Registration Number: NCT02533570

Locations: 🇺🇸
University of Alabama at Birmingham - (UAB), Birmingham, Alabama, United States
🇺🇸
TriWest Research Associates, LLC, El Cajon, California, United States
🇺🇸
Advanced Medical Research, LLC, La Palma, California, United States

and more 14 locations

Safety Study of SEA-CD40 in Cancer Patients

Phase 1

Terminated

Conditions: Neoplasms, Squamous Cell
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer Metastatic
Melanoma
Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Neoplasm
Pancreatic Adenocarcinoma
Carcinoma, Squamous Cell
Lymphoma, Large B-Cell, Diffuse
Non-small Cell Carcinoma

Interventions: Drug: Intravenous (IV) SEA-CD40
Drug: Subcutaneous (SC) SEA-CD40
Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2015-03-03

Last Posted Date: 2023-05-01

Lead Sponsor: Seagen Inc.

Target Recruit Count: 159

Registration Number: NCT02376699

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
🇺🇸
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy